PCSA Processa Pharmaceuticals posts worsethanexpected Q4 2025 EPS results that miss estimates by 68 percent as shares edge 033 percent lower 3 E MASK Stock Relative Valuation Review Geopolitical Middle East Tensions and Global Clean Energy Market Dynamics